Poster Poster Program Radiopharmaceuticals, Theranostics, and Nuclear Medicine

Case Report of a Clinically Significant Lu-177 Extravasation: Rapid Clearance Kinetics and Dosimetry Using Quantitative SPECT/CT

Abstract
Purpose

Extravasation during radiopharmaceutical therapy can retain a substantial fraction of administered activity at the injection site, creating high local absorbed doses and potential tissue injury while reducing delivery to target tumors. For Lu-177 therapies, timely quantitative assessment of infiltrated activity, clearance, and extravasation dosimetry is essential for patient management.

Methods

A patient receiving Lu-177 DOTATATE (Lutathera, 200 mCi) was identified with an extravasation early during administration; the infusion was stopped and IV access re-established. Local hyperthermia and arm elevation were used to promote clearance. Post-administration, infiltrated activity was quantified using (1) a hand-held CZT detector (RAVIN CAM) and (2) an xSPECT Quant protocol on a NaI SPECT/CT system. The first SPECT/CT defined the extravasated volume (VOI = 1070 mL) and activity, a second SPECT/CT 4.57 h later enabled effective half-life (Teff) estimation and patient-specific dosimetry with MIRDcalc (sphere model).

Results

Quantitative SPECT/CT estimated 66.6 mCi, while the external detector estimated 61.8 mCi (7% difference). SPECT/CT data showed a decrease from 66.6 mCi to 28.0 mCi over 4.57 h, yielding Teff = 3.66 h, consistent with rapid clearance. The mean absorbed dose to the 1070 mL infiltrated soft-tissue compartment was 1.035 Gy (self-dose only). Two low-dose CTs used for localization and attenuation correction had CTDIvol of 5.37 mGy each, corresponding to a total effective dose of 15 mSv calculated with MIRDct. The measured short Teff did not require more restrictive patient release criteria than the default 56.1 h value.

Conclusion

This case demonstrates a practical Lu-177 extravasation workflow: rapid identification with an external detector, quantitative SPECT/CT activity estimation, and a second time point for Teff-based dosimetry. Despite one-third of the planned activity infiltrating, rapid clearance limited the mean compartment dose to ~1 Gy, and patient release guidance remained within standard practice while incurring a low additional CT dose.

People

Related

Similar sessions

Poster Poster Program
Jul 19 · 07:00
Adverse Events in Targeted Radionuclide Therapy

Radiopharmaceutical therapy (RPT) plays an important role in the management of oncology patients, particularly those with thyroid cancer, prostate cancer, and neuroendocrine tumor. The use of radionuclide therapy has expanded rap...

Harrison L. Agordzo
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested
Poster Poster Program
Jul 19 · 07:00
Development of a Web-Based Theranostic Workflow Management Tool

To develop a Web-Based Theranostic Workflow Management Tool (TWMT) to efficiently manage Theranostic program in the department of radiation oncology (RadOnc).

Ling Zhuang, PhD
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested
Poster Poster Program
Jul 19 · 07:00
Epidseg-Net:the Multi-Modal Fusion Framework Based on Drr Guidance In Radiotherapy Is Used for Precise Segmentation of Epid Lung Targets

The proposed multimodal segmentation framework, named EPIDSeg-Net, comprises an encoder, a multi-scale feature layer, and a decoder. The encoder utilizes a dual-branch architecture: a CNN branch for extracting local texture featu...

Huang Qian Qianjia, M.Eng
Radiopharmaceuticals, Theranostics, and Nuclear Medicine 0 people interested